pCMV-S (also known as pRc/CMV-HBs) is widely used to validate DNA vaccine delivery and formulation strategies. This plasmid expresses the hepatitis B surface antigen (HBsAg) under the control of the CMV immediate-early promoter.
pCMVHB-S2.S expresses the small and middle forms of recombinant HBsAg. The plasmid can be used to generate anti-HBsAg antibodies like pCMV-S. It is also used to fuse other sequences to the S form of HBsAg.
The antibody response to pCMV-S and/or pCMVHB-S2.S can be tested via ELISA using recombinant HBsAg. Both of these plasmids are available free of charge for research applications. These vectors are covered and described by United States Patent 6,635,624 which is available at www.uspto.gov.
Plasmids for Vaccine Validation Quality Control Specifications
|Appearance||Clear and colorless|
|Concentration||5.0 mg/mL +/- 10%|
|DNA Homogeneity||Predominantly supercoiled|
|Endotoxin||≤ 100 EU/mg|
|Identity||Confirmed Against DNA Ladder|
|ABS 260/280 Ratio Purity||1.80 - 2.00|
|Residual Host Genomic DNA||≤ 5%|
|Residual Host RNA||Not visible at 200 ng load|